US Bioservices now dispenses ONPATTRO
August 13, 2018
The U.S. Food and Drug Administration has recently approved ONPATTRO (patisiran) for the treatment of adults with hereditary ATTR (hATTR) amyloidosis with symptomatic polyneuropathy.
.png?bc=ffffff&h=60&la=en&w=250&hash=D4E558BE41F5D9E7E7CC458758B16488B3D292F9){kind=logo}
The U.S. Food and Drug Administration has recently approved ONPATTRO (patisiran) for the treatment of adults with hereditary ATTR (hATTR) amyloidosis with symptomatic polyneuropathy.